# A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer

> **NCT07114315** · PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 160 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** AK112
- **DRUG:** AK130

## Key facts

- **NCT ID:** NCT07114315
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-19
- **Primary completion:** 2027-08
- **Final completion:** 2028-08
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07114315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07114315, "A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT07114315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*